Earnings ·
Nyxoah reports Q3 net revenue of €9.2 million, up 19% sequentially
NYXHNyxoah SA
Nyxoah SA reported third-quarter 2026 global net revenue of €9.2 million, representing a 19% sequential increase and a significant jump from €2.0 million in the prior-year quarter. U.S. net revenue grew 29% sequentially to €6.7 million, driven by continued commercial expansion following FDA approval. The company posted an operating loss of €21.9 million, narrowing from €24.4 million in Q3 2025, while maintaining a cash position of €77.1 million. Additionally, Nyxoah submitted a PMA supplement to the FDA to expand its Genio system indication to include Complete Concentric Collapse patients after meeting pivotal study endpoints. The company operates as a medical technology firm developing neuromodulation therapies for obstructive sleep apnea.